Showing posts with label mesothelioma lawyers. Show all posts
Showing posts with label mesothelioma lawyers. Show all posts

Wednesday, February 20, 2008

Boston Lawyer Michael Shepard Taking Mesothelioma, Personal Injury, Asbestos Cases

Seeking compensation for injury caused by asbestos exposure is now easy. A mesothelioma lawyer who started with his mesothelioma cancer law practice in Boston now brings his services to Vermont, New Hampshire and Rhode Island. People who are suffering from mesothelioma and other asbestos related injuries that have affected their health and wellbeing can rely on Michael Shepard to fight for their rights and help them in claiming compensation.

Michael Shepard has an established reputation of being a compassionate attorney who, along with mesothelioma and asbestos related injuries, also helps people in their pain and suffering arising out of injuries inflicted to them due to the faults of others. If people are injured due to exposure to toxic chemicals, product defects, nursing home negligence, silica, talc, welding fumes automotive or aviation accidents, they should contact the attorneys office to seek guidance for obtaining compensation for the injury caused.

In his website, the mesothelioma cancer lawyer acknowledges that the time of the injured is precious and says “We know our clients want the freedom to see family and friends whenever they choose. We also know that because of their condition, they don’t want to be bogged down in legal matters. Through years of experience in this field, we have developed a streamlined approach to handling asbestos-related litigation that lessens the amount of time our clients spend dealing with lawyers and the courts. After a client’s brief, free, one-on-one consultation with us, we take the matter into our own hands, independently investigating the specific facts of the case, collecting crucial evidence and confronting the people who are responsible for your illness or injury. We make every effort to transform our clients’ “good” case into a “great” case that may secure the maximum compensation deserved.”

Whether the injured is in Boston, Vermont, New Hampshire or Rhode Island, Boston Mesothelioma cancer lawyers are ready to look into the case and assess the maximum compensation during the first free one to one consultation.

Source

Wednesday, January 23, 2008

Vermont Mesothelioma Lawyer Shepard helping Mesothelioma Victims in Rhode Island, Boston, New York, New Hampshire

The Mesothelioma Lawyer expresses his concern over the student’s health risks as asbestos that was used in these old school buildings as the primary insulation and fireproofing construction material is now projecting from the school building sites due to poor maintenance. It is contaminating the schools environment posing students, teachers and the staff to mesothelioma cancer and asbestos related respiratory diseases.

The school going students and the staff working in these schools are exposed to the risk of asbestos related respirator diseases thus laying the foundation for mesothelioma. This fact is also reviled by the Mesothelioma and Asbestos Awareness Centers report. The school buildings in New York have now grown old and need maintenance. Due to lack of maintenance in the old building the asbestos which had been used in construction is now exposed. It is polluting the environment endangering the lives of students, teachers and staff exposing them to the risk of contracting asbestos related respiratory diseases and mesothelioma cancer.

During an emergency inspection in NY schools which was carried as a NY City School was blamed for an incident of asbestos exposure. It was reveled during the inspection that 80% of the building built prior to 1980 used asbestos as insulation and fire proof material during the construction phase. Now due to the poor maintenance the risk of exposure of asbestos has increased manifolds posing risk of health to all the occupants of the school buildings. The report by the Mesothelioma and Asbestos Awareness Centers Report also state that in 2004 one Brooklyn School was forced to open late as they had to ensure the safety of the school building, staff and the students.

Even a small amount of asbestos exposure contaminates the environment, increases the possibility of inhalation of asbestos particles thus marking a start of respiratory disorders leading to mesothelioma cancer.

Mesothelioma lawyer Shepard studies all such cases, takes the path of law to bring relief to the injured who had not known about the risks of being exposed to asbestos. At present Shepard Law Firm is assisting Mesothelioma victims in:
  • Boston
  • New Hampshire
  • Vermont
  • Rhode Island
However, due to large network Shepard Law firm enjoys, cases from other areas such as Dallas, New York, Houston and other areas where school buildings are getting old and may be of concern resulting in asbestos exposure can contact: The Shepard Law Firm at http://www.shepardlawfirm.com

To learn more about Mesothelioma / Asbestos Risks visit Mesothelioma Cancer Resource
for free informaation

Source

Friday, January 18, 2008

Alfacell Deals U.S. Rights for Onconase to Strativa

Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.

Just $5 million will change hands up front, but both Alfacell and Strativa stand to gain much more if their gamble in choosing each other as partners pays off. Specifically, Alfacell could get $30 million for FDA approval of Onconase in unresectable malignant mesothelioma (UMM) and up to $190 million for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications. Alfacell also would receive double-digit royalties and retains a co-promotion option.

For Alfacell, the gamble lies in choosing Strativa, the recently-launched specialty pharmaceutical division of Par Pharmaceutical Cos. Inc. So far, Strativa markets just one product: Megace ES for anorexia, cachexia and unexplained weight loss in HIV patients. Although the company has deals in place for three additional late-stage products, all three are for HIV or cancer supportive care, and Onconase would be Strativa's first true oncology therapeutic.

Lawrence Kenyon, executive vice president and chief financial officer for Alfacell, told BioWorld Today that Onconase has been the subject of "bids from multiple companies for a number of years." Strativa was selected because it had the hunger of a start-up looking to build an oncology business focused on niche products, combined with the resources and infrastructure of Par Pharmaceuticals, he said.

For Strativa, the gamble lies in Onconase's somewhat checkered development history. The drug, a natural ribonuclease isolated from frog eggs, failed a Phase III trial in pancreatic cancer and its first Phase III trial in UMM.

In the pancreatic cancer trial, a preliminary analysis showed that Onconase plus tamoxifen failed to improve survival compared to 5-fluorouracil. Kenyon said part of the problem was an inability to recruit sufficiently healthy patients into the trial, and the pancreatic cancer program subsequently was discontinued. (See BioWorld Today, July 16, 1998.)

The first Phase III UMM trial compared Onconase as a monotherapy to doxorubicin. Again, there was no survival difference in the overall population, but Kenyon said a retrospective analysis showed that the sickest patients had been disproportionately weighted to the Onconase group. Backing them out of the analysis resulted in a two-month survival difference.

Onconase is now being studied in a Phase IIIb trial designed to confirm the positive data seen in the Phase III subset analysis. The trial, which was designed in coordination with the FDA, compares Onconase plus doxorubicin to doxorubicin alone in the less-severe groups of UMM patients. Enrollment of 428 patients is complete, and Kenyon said the company is "very close" to obtaining the number of clinical events needed to analyze the data.

Under the deal with Strativa, Alfacell will continue to fund development, manufacturing and regulatory work with Onconase, including the ongoing Phase IIIb trial. Strativa will fund U.S. commercialization.

Previous deals with US Pharmacia affiliate USP Pharma Spolka Z.O.O. and Genesis Pharma SA cover Onconase commercialization in Eastern Europe and certain Southeast European countries, respectively.

As of Oct. 31, Alfacell reported $5.4 million in cash and equivalents, most of which was earmarked to support the Onconase trial and new drug application filing. Once the filing is submitted, Alfacell intends to work with Strativa on additional indications for Onconase, including the possibility of moving a non-small-cell lung cancer program into Phase II.

Kenyon said the money from Strativa also will allow Alfacell to "ramp up" its preclinical work on AC 03-636 for glioma and antiviral indications, AC CJ-001 for glioma, and AC CJ-002 for non-Hodgkin's lymphoma.

Shares of Somerset, N.J.-based Alfacell (NASDAQ:ACEL) rose 25 cents, or 14.3 percent, to close at $2 on Tuesday. Meanwhile, shares of Woodcliff Lake, N.J.-based Par Pharmaceuticals (NYSE:PRX) rose 52 cents to close at $21.49.

Source

Wednesday, January 9, 2008

Supreme Court hears ALCOA asbestos suit

Does a company have responsibility for people — other than its own employees — who are exposed to harmful agents from its facilities? That is the question the Tennessee Supreme Court tried to get its arms around Tuesday in Knoxville.
In late 2003, Maryville resident Amanda Satterfield, who was 23 years old at the time, filed a lawsuit against ALCOA Inc. and Breeding Insulation Co. in Blount County Circuit Court.

In her suit, Satterfield charged that she “was exposed to harmful asbestos dust and fibers from the day of her birth from her father’s use of asbestos products and inadvertent introduction of dust and fibers into their home and personal environments.” Satterfield had mesothelioma, a rare cancer directly associated with asbestos exposure.

On Jan. 1, 2005, at the age of 25, Satterfield lost her battle with cancer.
Doug Satterfield, Amanda’s father and the representative of her estate, continued with the suit after her death. With his 18-year-old daughter Amelia at his side, Doug Satterfield cried throughout the hearing in the Tennessee Supreme Court Building in downtown Knoxville.

Doug Satterfield hauled asbestos for ALCOA, starting his career with the company in 1973. He served in the military from 1975 to 1978 and then returned to work at ALCOA. His lawyers have maintained that Doug Satterfield was exposed to asbestos at ALCOA Tennessee Operations and that he brought home harmful dust and fibers on his clothes, resulting in Amanda contracting mesothelioma.

The lawsuit sought $10 million in compensatory and $10 million in punitive damages — although Satterfield has said the case is about justice and doing the right thing, not money.

ALCOA, represented by attorney John Lucas of Knoxville, argued that the ramifications of what the court is considering go far beyond this case, and could possibly create “an infinite universe of potential plaintiffs.”

Lucas referred to Satterfield’s allegations as the “conduit theory” — stating that, by assigning responsibility to companies for third-party contact with harmful agents, the court would define Doug Satterfield as the “vehicle” that transmitted asbestos into his home.

Tennessee Supreme Court Justice William Koch Jr. asked Lucas how that differed from an employee who drove an ALCOA truck into a neighborhood and exposed residents to asbestos.

“How is it negligent for ALCOA to let asbestos fly out of a truck and not negligent for ALCOA to allow employees to go home with asbestos dust on their clothing?” Koch asked.

ALCOA made a similar arguments during a coal tar pitch-related lawsuit in Knox County Chancery Court last year, charging that it would open the “floodgates of litigation” and that Tennessee would become a “plaintiff’s Mecca.” That case is now proceeding with a class action certification hearing following the conclusion of discovery depositions.

Knoxville attorney Greg Coleman, who represents Satterfield, said the real question was “what did ALCOA know, when did they know it, and what did they do about it?
“Public policy should at least extend to the home,” Coleman said. “ALCOA may not have known if an employee would stop at the Waffle House on his way home from work — but they did know that the employee would eventually end up at his home.”
Satterfield’s case has been in the legal system for more than four years. Originally heard — and dismissed — in Blount County Circuit Court Judge W. Dale Young’s court, the Tennessee Court of Appeals reversed Young’s decision, reinstated the lawsuit and charged ALCOA with the cost of the appeal in April 2007.

The Tennessee Supreme Court Justices are expected to issue a written opinion on the case within three months. They can either return the case to Blount County Circuit Court, where it will proceed, or dismiss it entirely.

After the hearing, Doug Satterfield told The Daily Times, “It seems like ALCOA is trying to change the law to protect itself.

“It’s unthinkable that public policy shouldn’t protect the children of workers.”

Amelia Satterfield, Amanda’s younger sister, said she believed the hearing went well, but said her family was nervous about the court appearance.

Coleman said: “ALCOA is trying to reverse what the law should be. They’re saying the greater the magnitude of the harm and the higher the mortality rate, the less responsibility they should have. Where I come from in Ducktown, Tennessee, that’s called bologna.”

The Tennessee Supreme Court should issue its written opinion by early April.

Source

LinkWithin